almagate has been researched along with triamcinolone in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakri, SJ; Diehl, N; Hillemeier, J; Hodge, DO; McCannel, CA; Pulido, JS | 1 |
| Menchini, F; Parravano, M; Virgili, G | 1 |
| Joussen, AM; Kakkassery, V; Winterhalter, S | 1 |
| Brunetti, M; Menchini, F; Parravano, M; Virgili, G | 1 |
| Evans, JR; Menchini, F; Parravano, M; Virgili, G | 1 |
| Aslankara, H; Kaynak, S; Koçak, N; Selım, A | 1 |
| Evans, JR; Gordon, I; Lucenteforte, E; Parravano, M; Virgili, G | 2 |
| Li, M; Qian, T; Wan, Y; Xu, X; Zhao, M | 1 |
7 review(s) available for almagate and triamcinolone
| Article | Year |
|---|---|
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Randomized Controlled Trials as Topic; Triamcinolone; Vascular Endothelial Growth Factor A | 2009 |
[Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Capillary Permeability; Clinical Trials as Topic; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Middle Aged; Off-Label Use; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinoscopy; Triamcinolone; Vascular Endothelial Growth Factor A | 2010 |
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Triamcinolone; Vascular Endothelial Growth Factor A | 2012 |
Anti-vascular endothelial growth factor for diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A | 2014 |
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2017 |
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Topics: Adrenal Cortex Hormones; Aptamers, Nucleotide; Dexamethasone; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Network Meta-Analysis; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Risk Assessment; Treatment Outcome; Triamcinolone; Vascular Endothelial Growth Factor A | 2018 |
4 other study(ies) available for almagate and triamcinolone
| Article | Year |
|---|---|
[Comments on current therapeutic possibilities for neovascular age-related macula degeneration].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Germany; Glucocorticoids; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Porphyrins; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnadienediols; Ranibizumab; Triamcinolone; Verteporfin | 2006 |
Macular degeneration. Advances in treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Glucocorticoids; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy; Pregnadienediols; Ranibizumab; Triamcinolone | 2006 |
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Injections, Intralesional; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Paracentesis; Remission, Spontaneous; Retinal Diseases; Triamcinolone | 2009 |
Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Female; Glucocorticoids; Humans; Intravitreal Injections; Macular Degeneration; Male; Photochemotherapy; Treatment Outcome; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |